Cargando…

Antihypertensive Therapy in the Acute Phase of Lacunar Infarcts

BACKGROUND: The optimal medical regimen for managing hypertension during acute phase of lacunar infarcts has not yet been clarified in real world setting. The aim of this study was to evaluate blood pressure lowering regimens on neurological progression and clinical outcomes during the acute phase o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Guanghui, Meng, Pin, Guo, Zhenwei, Liu, Na, Ji, Niu, Li, Xiaomin, Geng, Shan, He, Mingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166525/
https://www.ncbi.nlm.nih.gov/pubmed/30243025
http://dx.doi.org/10.12659/MSM.910183
_version_ 1783360056979357696
author Zhang, Guanghui
Meng, Pin
Guo, Zhenwei
Liu, Na
Ji, Niu
Li, Xiaomin
Geng, Shan
He, Mingli
author_facet Zhang, Guanghui
Meng, Pin
Guo, Zhenwei
Liu, Na
Ji, Niu
Li, Xiaomin
Geng, Shan
He, Mingli
author_sort Zhang, Guanghui
collection PubMed
description BACKGROUND: The optimal medical regimen for managing hypertension during acute phase of lacunar infarcts has not yet been clarified in real world setting. The aim of this study was to evaluate blood pressure lowering regimens on neurological progression and clinical outcomes during the acute phase of lacunar infarcts. MATERIAL/METHODS: For this study, 411 patients with first-episode lacunar infarcts and hypertension within 24 hours of symptom onset were included. All patients received antihypertension therapies, with different regimens, as well as routine medication during first 7 days after onset. There were 6 proposed antihypertensive treatments: calcium channel blockers (CCB), angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), β-blocker (β-B), and diuretic drug (DD) alone or in combination. Neurological progression was defined as worsening by ≥1 point in the National Institute of Health Stroke Scale (NIHSS) for motor function. The outcome was assessed using the modified Rankin Scale (mRS): favorable outcome (mRS of 0–1) or unfavorable outcome (mRS 2–5). RESULTS: Logistic regression analysis showed that combination therapy with CCB, ACEI/ARB, and β-B exhibited the lowest risk of deterioration (OR=0.48, P=0.019) and unfavorable outcomes (OR=0.50, P=0.022). Similarly, combination therapy with CCB, ACEI/ARB, and DD exhibited lower risk of deterioration (OR=0.63, P=0.033) and unfavorable outcome (OR=0.77, P=0.042) at 3 months. CONCLUSIONS: Rational blood pressure lowering was beneficial to the functional outcomes of patients during acute phase of lacunar infarcts, and combination therapy was better than mono-drug therapy.
format Online
Article
Text
id pubmed-6166525
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-61665252018-10-03 Antihypertensive Therapy in the Acute Phase of Lacunar Infarcts Zhang, Guanghui Meng, Pin Guo, Zhenwei Liu, Na Ji, Niu Li, Xiaomin Geng, Shan He, Mingli Med Sci Monit Clinical Research BACKGROUND: The optimal medical regimen for managing hypertension during acute phase of lacunar infarcts has not yet been clarified in real world setting. The aim of this study was to evaluate blood pressure lowering regimens on neurological progression and clinical outcomes during the acute phase of lacunar infarcts. MATERIAL/METHODS: For this study, 411 patients with first-episode lacunar infarcts and hypertension within 24 hours of symptom onset were included. All patients received antihypertension therapies, with different regimens, as well as routine medication during first 7 days after onset. There were 6 proposed antihypertensive treatments: calcium channel blockers (CCB), angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), β-blocker (β-B), and diuretic drug (DD) alone or in combination. Neurological progression was defined as worsening by ≥1 point in the National Institute of Health Stroke Scale (NIHSS) for motor function. The outcome was assessed using the modified Rankin Scale (mRS): favorable outcome (mRS of 0–1) or unfavorable outcome (mRS 2–5). RESULTS: Logistic regression analysis showed that combination therapy with CCB, ACEI/ARB, and β-B exhibited the lowest risk of deterioration (OR=0.48, P=0.019) and unfavorable outcomes (OR=0.50, P=0.022). Similarly, combination therapy with CCB, ACEI/ARB, and DD exhibited lower risk of deterioration (OR=0.63, P=0.033) and unfavorable outcome (OR=0.77, P=0.042) at 3 months. CONCLUSIONS: Rational blood pressure lowering was beneficial to the functional outcomes of patients during acute phase of lacunar infarcts, and combination therapy was better than mono-drug therapy. International Scientific Literature, Inc. 2018-09-22 /pmc/articles/PMC6166525/ /pubmed/30243025 http://dx.doi.org/10.12659/MSM.910183 Text en © Med Sci Monit, 2018 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Clinical Research
Zhang, Guanghui
Meng, Pin
Guo, Zhenwei
Liu, Na
Ji, Niu
Li, Xiaomin
Geng, Shan
He, Mingli
Antihypertensive Therapy in the Acute Phase of Lacunar Infarcts
title Antihypertensive Therapy in the Acute Phase of Lacunar Infarcts
title_full Antihypertensive Therapy in the Acute Phase of Lacunar Infarcts
title_fullStr Antihypertensive Therapy in the Acute Phase of Lacunar Infarcts
title_full_unstemmed Antihypertensive Therapy in the Acute Phase of Lacunar Infarcts
title_short Antihypertensive Therapy in the Acute Phase of Lacunar Infarcts
title_sort antihypertensive therapy in the acute phase of lacunar infarcts
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166525/
https://www.ncbi.nlm.nih.gov/pubmed/30243025
http://dx.doi.org/10.12659/MSM.910183
work_keys_str_mv AT zhangguanghui antihypertensivetherapyintheacutephaseoflacunarinfarcts
AT mengpin antihypertensivetherapyintheacutephaseoflacunarinfarcts
AT guozhenwei antihypertensivetherapyintheacutephaseoflacunarinfarcts
AT liuna antihypertensivetherapyintheacutephaseoflacunarinfarcts
AT jiniu antihypertensivetherapyintheacutephaseoflacunarinfarcts
AT lixiaomin antihypertensivetherapyintheacutephaseoflacunarinfarcts
AT gengshan antihypertensivetherapyintheacutephaseoflacunarinfarcts
AT hemingli antihypertensivetherapyintheacutephaseoflacunarinfarcts